about
A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewTreatment of patients with COPD and recurrent exacerbations: the role of infection and inflammationA review of national guidelines for management of COPD in EuropeAn official American Thoracic Society/European Respiratory Society statement: research questions in COPDChronic obstructive pulmonary diseaseAugmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachMortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics.Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study.Bronchiectasis in COPD patients: more than a comorbidity?Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of lifePhenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide.Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD.Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease.Effectiveness of anti-inflammatory treatment versus antibiotic therapy and placebo for patients with non-complicated acute bronchitis with purulent sputum. The BAAP Study protocol.Systemic inflammation in chronic obstructive pulmonary disease: a population-based study.Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease.Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systemsObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study.Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries.Epidemiology and costs of chronic obstructive pulmonary disease.Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial.The concept of control of COPD in clinical practice.A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.Caregivers' burden in patients with COPD.Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease.Economic valuation and determinants of informal care to disabled people with Chronic Obstructive Pulmonary Disease (COPD)Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDEffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study.Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.Difficulties in differential diagnosis of COPD and asthma in primary care.What pulmonologists think about the asthma-COPD overlap syndrome.Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
P50
Q26801661-0FE8A4FD-405A-41D1-9353-D0267D733BCBQ26823339-392D212D-7EA4-464D-8D11-140093884B2AQ28070274-662B8289-B2A7-4313-AB9B-45D4B84F4A6CQ28071694-C849DA22-C657-4668-B06C-1788C5EAB59EQ28072014-6EC70FDE-38E0-4EE9-B024-CD061B3BC391Q28080983-643A9BF9-3667-4091-8A14-C06275C22266Q28259151-1666A1EE-5877-4975-AB13-CD0995319F2EQ28392320-C1188708-88D6-4503-B879-6C1EABB429DEQ30955660-7BAA2873-05AC-4AE0-8F08-473406ED7DD4Q33596502-8A6C9297-A582-4230-9760-B2FF85525015Q33597458-E6D3F47A-A30F-4577-BEFC-2D8FAEDA08F5Q33704105-97FC3E50-015A-4C97-8291-2DFB46338CFCQ33711672-F5F99E97-64E5-4BAD-A41C-9EB853BD5919Q33743024-B7FC00BD-6E52-4F2D-ADDD-5A04F58125ABQ33755801-59680A44-CF0E-48A2-B1F6-B6533B10EC11Q33768773-CEE7C979-9DAE-452B-A258-E210EEAF8207Q33806741-CA027C2B-CF7F-430A-9F46-347B6CD5D7E4Q33824230-2B710E4A-B224-4923-97D6-9F741150CE15Q33905336-8A78552D-BF7C-4290-AF87-4D7374F33879Q33938614-41654312-5E7E-4AF7-B07A-55B7B2D1E005Q33939195-47925311-4ADD-481C-B7ED-F419C33FA296Q34083585-FF5A2A43-DD9C-4199-BD1E-DF6D790010C6Q34134884-8987DE7F-2195-47FB-B331-0839EAD7CBB1Q34235044-7A70A479-E9F9-4A30-A272-F469DF31FA68Q34451879-7F831F9C-097C-4EAD-8838-D2D8F698AE5CQ34563826-0AE7E694-2DB5-4114-9E98-2DD693019DCBQ34563833-2FF8FA57-B18D-4454-B92A-C04AC2DA8360Q34656522-BEEF2328-CF4C-4F3B-A5A9-6DFE5ABBC342Q34742591-1DE5A86E-3275-43ED-B894-F27A9AC259D6Q35096997-C671B591-75CF-409E-A492-BEF94BCD2B88Q35100912-D46316F2-0900-4A5C-AE1E-51FD4C60A9B0Q35108231-BE1C551E-FE1C-41B1-B251-FDC90ECD9124Q35111195-7843804C-00BD-43F2-AE17-F5821055F97DQ35215700-4B6392CF-6955-4629-8E28-C9652822989BQ35535912-78C5A565-5D4F-49FA-8E82-AAFF7C685A6DQ35536623-6BC1D6AC-C1E9-43C8-8E51-D9DFE7137471Q35694431-FD9FFBC0-4A63-4348-81BC-6256015804F5Q35710447-07B2FEC6-5654-4DC1-942E-E02D89FBEBE3Q35867095-88E21B50-C048-4B3E-BACD-8EAF3AB07862Q35878722-B7976C98-9E53-4B5A-9F47-DB8C94DA3FCB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marc Miravitlles
@en
Marc Miravitlles
@hy
Marc Miravitlles
@nl
Marc Miravitlles
@sq
type
label
Marc Miravitlles
@en
Marc Miravitlles
@hy
Marc Miravitlles
@nl
Marc Miravitlles
@sq
altLabel
Marc Miravitlles
@en
prefLabel
Marc Miravitlles
@en
Marc Miravitlles
@hy
Marc Miravitlles
@nl
Marc Miravitlles
@sq
P214
P950
P106
P1153
7004909276
P21
P213
0000 0000 5993 0748
P214
P31
P496
0000-0002-9850-9520
P569
1991-12-01T00:00:00Z
P735
P7859
lccn-n2013187976